Form 4 for ABT Abbott Laboratories
Accepted 2021-12-15 00:00:00 ET · period of report 2021-12-13 · accession 0001415889-21-005967 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-12-15 | 2021-12-13 | ABT | Salvadori Daniel Gesua Sive | EVP | M - OptEx | $41.81 | +55.0K | 158.9K | +53% | +$2.30M |
| DM | 2021-12-15 | 2021-12-13 | ABT | Salvadori Daniel Gesua Sive | EVP | S - Sale+OE | $135.00 | -58.5K | 103.9K | -36% | -$7.90M |
| DM | 2021-12-15 | 2021-12-13 | ABT | Salvadori Daniel Gesua Sive | EVP | M - OptEx | $0.00 | -55.0K | 60.8K | -47% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common shares without par value | 2021-12-13 | M | A | 23,771 | $38.40 | 127,702 | D | — | — | |
| 2 | Common | Common shares without par value | 2021-12-13 | S | D | 3,499 | $135.00 | 103,931 | D | — | — | |
| 3 | Common | Common shares without par value | 2021-12-13 | M | A | 31,229 | $44.40 | 158,931 | D | — | — | |
| 4 | Common | Common shares without par value | 2021-12-13 | S | D | 55,000 | $135.00 | 103,931 | D | — | — | |
| 5 | Derivative | Option (right to buy) | 2021-12-13 | M | D | 23,771 | $0.00 | 47,542 | D | $38.40 · 2019-02-19 to 2026-02-18 | 23,771 Common Shares | (F1) Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| 6 | Derivative | Option (right to buy) | 2021-12-13 | M | D | 31,229 | $0.00 | 60,803 | D | $44.40 · 2020-02-17 to 2027-02-16 | 31,229 Common Shares | (F1) Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |